You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePethidine
Accession NumberDB00454  (APRD00074)
TypeSmall Molecule
GroupsApproved
DescriptionA narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. [PubChem]
Structure
Thumb
Synonyms
Isonipecaïne
Meperidine
Pethidin
Péthidine
Pethidine dbl
Pethidinum
Petidina
Petydyna
Sauteralgyl
Spasmedal
Spasmodolin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DemerolInjection, solution100 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolTablet50 mg/1OralSanofi Aventis U.S. Llc1942-11-10Not applicableUs
DemerolInjection, solution100 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolInjection, solution50 mg/mLIntramuscular; Intravenous; SubcutaneousPhysicians Total Care, Inc.2007-08-21Not applicableUs
DemerolInjection, solution50 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolTablet50 mg/1OralValidus Pharmaceuticals LLC1942-11-10Not applicableUs
DemerolTablet100 mg/1OralSanofi Aventis U.S. Llc1942-11-10Not applicableUs
DemerolInjection, solution50 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolInjection, solution25 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolTablet50 mg/1Oralbryant ranch prepack2013-04-01Not applicableUs
DemerolInjection, solution75 mg/1.5mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolTablet100 mg/1OralValidus Pharmaceuticals LLC1942-11-10Not applicableUs
DemerolInjection, solution50 mg/mLIntramuscular; Intravenous; SubcutaneousPhysicians Total Care, Inc.1994-04-11Not applicableUs
DemerolInjection, solution100 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolInjection, solution50 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolTablet50 mgOralSanofi Aventis Canada Inc1944-12-31Not applicableCanada
DemerolInjection, solution100 mg/2mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolInjection, solution100 mg/mLIntramuscular; Intravenous; SubcutaneousPhysicians Total Care, Inc.2003-03-11Not applicableUs
DemerolInjection, solution25 mg/.5mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
DemerolInjection, solution75 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerol 50mg - Liq Im IV Sc 50mg/mlLiquid50 mgIntramuscular; Intravenous; SubcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 50mg - Liq Im Sc 50mg/mlLiquid50 mgIntramuscular; SubcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 10%-liq Im IV ScLiquid100 mgIntramuscular; Intravenous; SubcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 10%-liq Im Sc 100mg/mlLiquid100 mgIntramuscular; SubcutaneousSanofi Canada, Inc.1944-12-312001-08-17Canada
Demerol 100 mg/mlSolution100 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation2000-08-15Not applicableCanada
Demerol 100 mg/mlSolution100 mgIntramuscular; SubcutaneousHospira Healthcare Corporation2000-05-01Not applicableCanada
Demerol 50 mg/ml (multiple Dose With Metacresol As Preservative)Solution50 mgIntramuscular; SubcutaneousHospira Healthcare Corporation2000-12-012012-08-03Canada
Demerol 50 mg/ml (single Use, Preservative Free)Solution50 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation2000-12-01Not applicableCanada
Demerol 75 mg/mlSolution75 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation2000-12-01Not applicableCanada
Demerol 75mg - Liq Im IV Sc 75mg/mlLiquid75 mgIntramuscular; Intravenous; SubcutaneousSanofi Canada, Inc.1969-12-312001-08-10Canada
Meperidine HCl Injection 100mg/mlSolution100 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 10mg/mlSolution10 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 25mg/mlSolution25 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 50mg/mlSolution50 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 75mg/mlSolution75 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine Hydrochloride Injection USPSolution10 mgIntravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPSolution75 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPSolution50 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPSolution100 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1988-12-31Not applicableCanada
Pethidine Injection B.P.Solution10 mgIntravenousHospira Healthcare Corporation1998-09-242012-08-03Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meperidine HydrochlorideTablet50 mg/1OralEpic Pharma, LLC2011-05-05Not applicableUs
Meperidine HydrochlorideTablet75 mg/1OralMikart, Inc.2009-06-24Not applicableUs
Meperidine HydrochlorideSolution50 mg/5mLOralWest Ward Pharmaceuticals Corp.1985-01-30Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralBarr Laboratories Inc.1997-02-03Not applicableUs
Meperidine HydrochlorideInjection50 mg/mLIntramuscularPhysicians Total Care, Inc.2010-03-04Not applicableUs
Meperidine HydrochlorideInjection, solution10 mg/mLIntravenousHospira, Inc.1984-08-16Not applicableUs
Meperidine HydrochlorideInjection50 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralEpic Pharma, LLC2011-05-05Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralMikart, Inc.2009-06-24Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralWest Ward Pharmaceuticals Corp.1997-03-12Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralBarr Laboratories Inc.1996-10-112016-07-31Us
Meperidine HydrochlorideTablet50 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2007-01-04Not applicableUs
Meperidine HydrochlorideInjection100 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralQualitest Pharmaceuticals1998-12-17Not applicableUs
Meperidine HydrochlorideTablet150 mg/1OralMikart, Inc.2009-06-24Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralWest Ward Pharmaceuticals Corp.1997-03-12Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralBarr Laboratories Inc.2015-02-24Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2007-01-04Not applicableUs
Meperidine HydrochlorideTablet100 mg/1OralQualitest Pharmaceuticals1998-12-17Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralMikart, Inc.2009-06-24Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralPhysicians Total Care, Inc.2009-09-14Not applicableUs
Meperidine HydrochlorideTablet50 mg/1OralWest Ward Pharmaceuticals Corp.1997-03-12Not applicableUs
Meperidine HydrochlorideInjection25 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine HydrochlorideTablet50 mg/1Oralbryant ranch prepack1998-12-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meperidine HClInjection, solution10 mg/mLIntravenousCantrell Drug Company2012-01-23Not applicableUs
International Brands
NameCompany
Dolantinsanofi-aventis
Dolcontralmibe
DolosalCristália
DolsinBiotika
LydolSopharma
MialginZentiva
PetidinNycomed
Brand mixtures
NameLabellerIngredients
Meperidine Hydrochloride and Promethazine HydrochlorideEci Pharmaceuticals Llc
Salts
Name/CASStructureProperties
Meperidine hydrochloride
ThumbNot applicableDBSALT001046
Pethidine hydrochloride
Thumb
  • InChI Key: WCNLCIJMFAJCPX-UHFFFAOYSA-N
  • Monoisotopic Mass: 283.13390666
  • Average Mass: 283.794
DBSALT000628
Categories
UNII9E338QE28F
CAS number57-42-1
WeightAverage: 247.3327
Monoisotopic: 247.157228921
Chemical FormulaC15H21NO2
InChI KeyXADCESSVHJOZHK-UHFFFAOYSA-N
InChI
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
IUPAC Name
ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
SMILES
CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
Pharmacology
IndicationUsed to control moderate to severe pain.
Structured Indications
PharmacodynamicsMeperidine is a synthetic opiate agonist belonging to the phenylpiperidine class. Meperidine may produce less smooth muscle spasm, constipation, and depression of the cough reflex than equivalent doses of morphine. The onset of action is lightly more rapid than with morphine, and the duration of action is slightly shorter. The chemical structure of meperidine is similar to local anesthetics. Meperidine is recommended for relief of moderate to severe acute pain and has the unique ability to interrupt postoperative shivering and shaking chills induced by amphotericin B. Meperidine has also been used for intravenous regional anesthesia, peripheral nerve blocks and intraarticular, epidural and spinal analgesia. Meperidine is considered a second-line agent for the treatment of acute pain.
Mechanism of actionMeperidine is primarily a kappa-opiate receptor agonist and also has local anesthetic effects. Meperidine has more affinity for the kappa-receptor than morphine. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Kappa-type opioid receptorProteinyesNot AvailableHumanP41145 details
Glutamate receptor ionotropic, NMDA 1Proteinunknown
antagonist
HumanQ05586 details
Glutamate receptor ionotropic, NMDA 2BProteinunknown
antagonist
HumanQ13224 details
Glutamate receptor ionotropic, NMDA 2AProteinunknown
antagonist
HumanQ12879 details
Glutamate receptor ionotropic, NMDA 2CProteinunknown
antagonist
HumanQ14957 details
Glutamate receptor ionotropic, NMDA 2DProteinunknown
antagonist
HumanO15399 details
Muscarinic acetylcholine receptorProtein groupunknown
binder
Humannot applicabledetails
Mu-type opioid receptorProteinunknown
agonist
HumanP35372 details
Sodium-dependent dopamine transporterProteinunknownNot AvailableHumanQ01959 details
Sodium-dependent noradrenaline transporterProteinunknownNot AvailableHumanP23975 details
Sodium-dependent serotonin transporterProteinunknown
binding
HumanP31645 details
Related Articles
AbsorptionThe oral bioavailability of meperidine in patients with normal hepatic function is 50-60% due to extensive first-pass metabolism. Bioavailability increases to 80-90% in patients with hepatic impairment (e.g. liver cirrhosis). Meperidine is less than half as effective when administered orally compared to parenteral administration. One study reported that 80-85% of the drug administered intramuscularly was absorbed within 6 hours of intragluteal injection in health adults; however, inter-individual variation and patient-specific variable appear to cause considerable variations in absorption upon IM injection.
Volume of distribution

Meperidine crosses the placenta and is distributed into breast milk.

Protein binding60-80% bound to plasma proteins, primarily albumin and α1-acid glycoprotein. The presence of cirrhosis or active viral hepatitis does not appear to affect the extent of protein binding.
Metabolism

Meperidine is metabolized in the liver by hydrolysis to meperidinic acid followed by partial conjugation with glucuronic acid. Meperidine also undergoes N-demethylation to normeperidine, which then undergoes hydrolysis and partial conjugation. Normeperidine is about half as potent as meperidine, but it has twice the CNS stimulation effects.

Route of eliminationExcreted in the urine. The proportion of drug that is excreted unchanged or as metabolites is dependent on pH. When urine pH is uncontrolled, 5-30% of the meperidine dose is excreted as normeperidine and approximately 5% is excreted unchanged. Meperidine and normeperidine are found in acidic urine, while the free and conjugated forms of meperidinic and normperidinic acids are found in alkaline urine.
Half lifeInitial distribution phase (t1/2 α) = 2-11 minutes; terminal elimination phase (t1/2 β) = 3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t1/2 β is prolonged to 7-11 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Pethidine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pethidine.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pethidine.Experimental, Illicit
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Pethidine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pethidine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Pethidine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Pethidine.Experimental
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pethidine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Pethidine.Experimental
AbirateroneThe serum concentration of Pethidine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Acetophenazine.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pethidine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Pethidine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pethidine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Pethidine.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Almotriptan.Approved, Investigational
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Pethidine.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Pethidine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pethidine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pethidine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Pethidine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Pethidine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pethidine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Pethidine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Pethidine.Approved, Illicit
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Pethidine.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pethidine.Approved
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Pethidine.Approved
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Pethidine.Approved
AprepitantThe serum concentration of Pethidine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Pethidine.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Pethidine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Pethidine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Pethidine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Asenapine.Approved
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Pethidine.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Pethidine.Approved, Investigational
AtomoxetineThe metabolism of Pethidine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pethidine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pethidine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Azaperone.Vet Approved
AzelastinePethidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Pethidine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Pethidine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Experimental
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Illicit
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Pethidine.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pethidine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pethidine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Pethidine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Pethidine is combined with Benperidol.Investigational
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Pethidine.Experimental
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pethidine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Pethidine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Pethidine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Pethidine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The risk or severity of adverse effects can be increased when Bi201335 is combined with Pethidine.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Pethidine is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pethidine.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Pethidine.Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Pethidine.Approved
BortezomibThe metabolism of Pethidine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pethidine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pethidine.Approved, Investigational
BuprenorphinePethidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Pethidine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pethidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pethidine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Pethidine is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Pethidine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pethidine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pethidine.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Pethidine.Experimental
Canrenoic acidThe risk or severity of adverse effects can be increased when Pethidine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pethidine.Approved
CarbamazepineThe metabolism of Pethidine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pethidine is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Pethidine.Withdrawn
CelecoxibThe metabolism of Pethidine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pethidine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Pethidine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Pethidine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pethidine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Pethidine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Pethidine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Pethidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Pethidine.Experimental
CicletanineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cicletanine.Investigational
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Pethidine.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.Approved
CimetidineThe serum concentration of Pethidine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Pethidine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Pethidine.Approved
ClarithromycinThe metabolism of Pethidine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pethidine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pethidine is combined with Clidinium.Approved
ClobazamThe metabolism of Pethidine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonidine.Approved
ClopidogrelThe metabolism of Pethidine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Pethidine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Pethidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Pethidine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Pethidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pethidine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pethidine.Approved, Illicit
ConivaptanThe serum concentration of Pethidine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Pethidine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pethidine.Approved
CyclosporineThe metabolism of Pethidine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.Approved
DabrafenibThe serum concentration of Pethidine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pethidine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pethidine.Investigational
DarifenacinThe metabolism of Pethidine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Pethidine.Approved
DasatinibThe serum concentration of Pethidine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pethidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pethidine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Pethidine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Pethidine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pethidine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Pethidine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Pethidine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Pethidine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pethidine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Pethidine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Pethidine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Pethidine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenoxylate.Approved, Illicit
DolasetronDolasetron may increase the serotonergic activities of Pethidine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Pethidine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Pethidine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Pethidine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pethidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pethidine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Illicit
DronedaroneThe metabolism of Pethidine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pethidine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.Approved
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Pethidine.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pethidine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Pethidine is combined with Ecopipam.Investigational
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Pethidine.Approved
EfavirenzThe serum concentration of Pethidine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efonidipine.Approved
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Pethidine.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pethidine.Approved, Investigational
EliglustatThe metabolism of Pethidine can be decreased when combined with Eliglustat.Approved
EluxadolinePethidine may increase the constipating activities of Eluxadoline.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pethidine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Pethidine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pethidine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pethidine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Pethidine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergotamine.Approved
ErythromycinThe metabolism of Pethidine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pethidine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pethidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Pethidine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pethidine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.Approved
EthanolPethidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pethidine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pethidine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pethidine.Approved
EtoperidonePethidine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Pethidine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pethidine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Pethidine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Pethidine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Pethidine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Pethidine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Pethidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Pethidine.Approved
FosaprepitantThe serum concentration of Pethidine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.Approved
FosphenytoinThe serum concentration of Pethidine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pethidine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Pethidine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Pethidine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Pethidine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pethidine is combined with gabapentin enacarbil.Approved
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Pethidine.Investigational
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pethidine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pethidine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Pethidine.Experimental
GemfibrozilThe metabolism of Pethidine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pethidine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pethidine.Approved, Investigational, Vet Approved
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Pethidine.Experimental
GranisetronGranisetron may increase the serotonergic activities of Pethidine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Pethidine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Pethidine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Pethidine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pethidine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pethidine.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Pethidine.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pethidine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Pethidine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePethidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Pethidine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pethidine.Approved
IdelalisibThe serum concentration of Pethidine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Pethidine.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Iloperidone.Approved
ImatinibThe metabolism of Pethidine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pethidine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Imipramine.Approved
IndalpinePethidine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Pethidine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.Approved
IproclozideIproclozide may increase the serotonergic activities of Pethidine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Pethidine.Withdrawn
IsavuconazoniumThe metabolism of Pethidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Pethidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pethidine.Approved, Withdrawn
IsoniazidThe metabolism of Pethidine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Pethidine is combined with Isosorbide.Approved
IsradipineThe metabolism of Pethidine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Pethidine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pethidine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Pethidine.Approved
KetamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Pethidine can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Pethidine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lamotrigine.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Pethidine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pethidine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pethidine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Pethidine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Pethidine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Pethidine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Lofentanil.Illicit
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pethidine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Pethidine is combined with Lorcaserin.Approved
LovastatinThe metabolism of Pethidine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pethidine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Pethidine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Pethidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pethidine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Pethidine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pethidine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Pethidine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Pethidine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Pethidine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Pethidine.Investigational
MephentermineMephentermine may increase the analgesic activities of Pethidine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Pethidine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pethidine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pethidine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Pethidine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pethidine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
MethotrimeprazinePethidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the serotonergic activities of Pethidine.Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Pethidine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Pethidine is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.Approved
MetoprololThe metabolism of Pethidine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosinePethidine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Pethidine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pethidine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Pethidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Investigational
MirabegronThe metabolism of Pethidine can be decreased when combined with Mirabegron.Approved
MirtazapinePethidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Pethidine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Pethidine.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Pethidine.Approved
ModafinilThe serum concentration of Pethidine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Pethidine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pethidine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Pethidine.Experimental
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Pethidine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pethidine.Investigational
NafcillinThe serum concentration of Pethidine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Pethidine.Approved
NaltrexoneThe therapeutic efficacy of Pethidine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Naratriptan.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Pethidine.Investigational
NefazodoneThe metabolism of Pethidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Pethidine.Approved
NetupitantThe serum concentration of Pethidine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pethidine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Pethidine.Withdrawn
NicardipineThe metabolism of Pethidine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Pethidine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrazepam.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pethidine.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Pethidine.Investigational
OctamoxinOctamoxin may increase the serotonergic activities of Pethidine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine.Approved, Investigational
OlaparibThe metabolism of Pethidine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olopatadine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pethidine.Investigational
OmeprazoleThe metabolism of Pethidine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Pethidine.Approved
OpiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Opium.Approved, Illicit
OrphenadrinePethidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Pethidine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Pethidine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pethidine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pethidine.Approved
PalbociclibThe serum concentration of Pethidine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Pethidine.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pethidine.Approved
PanobinostatThe serum concentration of Pethidine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pethidine can be decreased when combined with Pantoprazole.Approved
ParaldehydePethidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the serotonergic activities of Pethidine.Approved
ParoxetineThe metabolism of Pethidine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pethidine.Approved
PentazocinePentazocine may decrease the analgesic activities of Pethidine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pethidine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pethidine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perphenazine.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Pethidine.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Pethidine.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Pethidine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Pethidine.Approved, Illicit
PhenytoinThe serum concentration of Pethidine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Pethidine.Experimental
PimozideThe risk or severity of adverse effects can be increased when Pethidine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pethidine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pethidine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Pethidine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Pethidine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pethidine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Pethidine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.Approved, Vet Approved
PramipexolePethidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pethidine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prilocaine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Pethidine.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pethidine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pethidine.Approved
PromazineThe metabolism of Pethidine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pethidine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Pethidine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Pethidine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Pethidine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Pethidine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pethidine.Approved
PSD502The risk or severity of adverse effects can be increased when Pethidine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Pethidine.Approved
QuazepamThe serum concentration of Pethidine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Quinethazone.Approved
QuinidineThe metabolism of Pethidine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Pethidine can be decreased when combined with Quinine.Approved
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Pethidine.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Pethidine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Pethidine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pethidine.Approved
RamosetronPethidine may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Pethidine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Pethidine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Remifentanil.Approved
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Pethidine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pethidine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pethidine.Approved
RifabutinThe metabolism of Pethidine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pethidine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pethidine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pethidine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Pethidine.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Pethidine.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Pethidine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Pethidine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Pethidine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Romifidine.Vet Approved
RopinirolePethidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine.Approved
RotigotinePethidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pethidine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pethidine is combined with S-Ethylisothiourea.Experimental
SafrazineSafrazine may increase the serotonergic activities of Pethidine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Pethidine is combined with Sage 547.Investigational
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Pethidine.Approved, Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Pethidine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pethidine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Pethidine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Pethidine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pethidine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Pethidine.Approved
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Pethidine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pethidine.Approved
SorafenibThe metabolism of Pethidine can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pethidine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Pethidine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Pethidine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Pethidine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Pethidine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pethidine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Sumatriptan.Approved, Investigational
SuvorexantPethidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pethidine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Pethidine.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Pethidine.Approved
TelithromycinThe metabolism of Pethidine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pethidine.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pethidine.Experimental, Investigational
TerbinafineThe metabolism of Pethidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrodotoxin.Investigational
ThalidomidePethidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Pethidine is combined with Theobromine.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pethidine.Withdrawn
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Pethidine can be decreased when combined with Thioridazine.Approved
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Pethidine.Experimental
ThiotepaThe metabolism of Pethidine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Pethidine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Pethidine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pethidine.Approved
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Pethidine.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Pethidine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Pethidine.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pethidine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Pethidine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pethidine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pethidine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Pethidine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Pethidine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pethidine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pethidine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pethidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Pethidine.Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pethidine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pethidine.Approved
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Pethidine.Experimental
Uc1010The risk or severity of adverse effects can be increased when Pethidine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ularitide.Investigational
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Pethidine.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Pethidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pethidine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Pethidine.Approved
VerapamilThe metabolism of Pethidine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Pethidine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Vilazodone.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Pethidine.Approved, Investigational
VoriconazoleThe metabolism of Pethidine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Pethidine is combined with Vortioxetine.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Pethidine.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Xylazine.Vet Approved
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Pethidine.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Pethidine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziconotide.Approved
ZimelidinePethidine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pethidine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pethidine.Approved, Investigational
ZolpidemPethidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02AB72N02AB52N02AG03N02AB02
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (173 KB)
MSDSDownload (6.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9947
Blood Brain Barrier+0.9876
Caco-2 permeable+0.6683
P-glycoprotein substrateSubstrate0.7821
P-glycoprotein inhibitor IInhibitor0.5174
P-glycoprotein inhibitor IIInhibitor0.5401
Renal organic cation transporterInhibitor0.6375
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateSubstrate0.8826
CYP450 3A4 substrateSubstrate0.5073
CYP450 1A2 substrateNon-inhibitor0.6897
CYP450 2C9 inhibitorNon-inhibitor0.6691
CYP450 2D6 inhibitorInhibitor0.7415
CYP450 2C19 inhibitorNon-inhibitor0.7635
CYP450 3A4 inhibitorNon-inhibitor0.6876
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5547
Ames testNon AMES toxic0.8694
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.9145
Rat acute toxicity3.1526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8593
hERG inhibition (predictor II)Inhibitor0.5813
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Sanofi aventis us llc
  • Abbott laboratories pharmaceutical products div
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Elkins sinn div ah robins co inc
  • International medication systems ltd
  • Parke davis div warner lambert co
  • Watson laboratories inc
  • International medication system
  • Mallinckrodt chemical inc
  • Roxane laboratories inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mallinckrodt inc
  • Mikah pharma llc
  • Mikart inc
  • Mutual pharmaceutical co inc
  • Vintage pharmaceuticals inc
  • Wyeth ayerst laboratories
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous; Subcutaneous100 mg/2mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous100 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous25 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous25 mg/.5mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous50 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous75 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous75 mg/1.5mL
TabletOral100 mg/1
TabletOral50 mg/1
TabletOral50 mg
LiquidIntramuscular; Intravenous; Subcutaneous50 mg
LiquidIntramuscular; Subcutaneous50 mg
LiquidIntramuscular; Intravenous; Subcutaneous100 mg
LiquidIntramuscular; Subcutaneous100 mg
SolutionIntramuscular; Intravenous; Subcutaneous100 mg
SolutionIntramuscular; Subcutaneous100 mg
SolutionIntramuscular; Subcutaneous50 mg
SolutionIntramuscular; Intravenous; Subcutaneous50 mg
SolutionIntramuscular; Intravenous; Subcutaneous75 mg
LiquidIntramuscular; Intravenous; Subcutaneous75 mg
Injection, solutionIntravenous10 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous25 mg
InjectionIntramuscular50 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous100 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous25 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous50 mg/mL
SolutionOral50 mg/5mL
TabletOral150 mg/1
TabletOral75 mg/1
CapsuleOral
SolutionIntravenous10 mg
Prices
Unit descriptionCostUnit
Meperidine HCl 100 mg/ml vial33.99USD vial
Meperidine hcl powder10.51USD g
Demerol 100 mg tablet3.33USD tablet
Demerol 100 mg/ml vial1.79USD ml
Demerol 50 mg tablet1.71USD tablet
Meperidine HCl 100 mg tablet1.33USD tablet
Meperidine 100 mg tablet1.31USD tablet
Demerol 100 mg/ml ampul1.1USD ml
Meperidine Hydrochloride 100 mg/ml1.1USD ml
Meperidine Hydrochloride 75 mg/ml1.04USD ml
Meperidine Hydrochloride 50 mg/ml0.98USD ml
Meperidine HCl 50 mg tablet0.93USD tablet
Demerol 50 mg/ml vial0.85USD ml
Meperidine 10 mg/ml syringe0.85USD ml
Meperidine 50 mg tablet0.69USD tablet
Demerol 50 mg/ml ampul0.58USD ml
Meperidine 10 mg/ml cartrdge0.3USD ml
Demerol 50 mg Tablet0.16USD tablet
Meperidine HCl 50 mg/5ml Solution0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility3220 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.72SANGSTER (1994)
logS-1.89ADME Research, USCD
pKa8.59SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.11 mg/mLALOGPS
logP2.9ALOGPS
logP2.46ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.48 m3·mol-1ChemAxon
Polarizability28.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9620000000-7309f4ee3918ea05f00dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylacetate
  • Piperidinecarboxylic acid
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Gene Name:
GRIN2A
Uniprot ID:
Q12879
Molecular Weight:
165281.215 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2C
Uniprot ID:
Q14957
Molecular Weight:
134207.77 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2D
Uniprot ID:
O15399
Molecular Weight:
143750.685 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Hustveit O: Binding of fentanyl and pethidine to muscarinic receptors in rat brain. Jpn J Pharmacol. 1994 Jan;64(1):57-9. [PubMed:8164394 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B: From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem. 2001 Oct 11;44(21):3378-90. [PubMed:11585443 ]
  2. Bryant, Bronwen (2010). Pharmacology for Health Professionals (Paperback) (3rd ed.). Chatswood: Mosby Australia. [ISBN:978-0-7295-3929-6 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Lomenzo SA, Izenwasser S, Gerdes RM, Katz JL, Kopajtic T, Trudell ML: Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3273-6. [PubMed:10612583 ]
  2. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  3. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  2. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binding
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  2. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Edwards DJ, Svensson CK, Visco JP, Lalka D: Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet. 1982 Sep-Oct;7(5):421-33. [PubMed:6754208 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Edwards DJ, Svensson CK, Visco JP, Lalka D: Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet. 1982 Sep-Oct;7(5):421-33. [PubMed:6754208 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23